Chronic Hepatitis B infection and liver cancer

Wong, Choon-Heng; Goh, Khean‐Lee

doi:10.2349/biij.2.2.e7

Cited by 3 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In natural history studies, the incidence of HBV‐related HCC reportedly differed between Asians and Caucasians, possibly because of differences in the mode and timing of HBV transmission or distribution of viral genotypes 57,58 . In contrast, HCC incidence while on antiviral therapy in the Caucasian population appears to be comparable with that in the Asian population or populations with mixed ethnicities (Fig.…”

Section: Discussionmentioning

confidence: 99%

Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review

Tseng

Hsu

et al. 2020

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have been shown to reduce incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This systematic review aims to evaluate the magnitude, change over time, and prediction of residual HCC risks in CHB patients treated with ETV/TDF therapy. Methods: Available literature was systematically reviewed through searches of PubMed and EMBASE databases from January 1, 2006 to September 1, 2019, to identify cohort studies that reported HCC incidence in CHB patients during ETV/TDF therapy. Studies were screened by title and abstract and then evaluated for eligibility in terms of full text. Results: We identified 141 studies for full-text review, and 34 were eligible for analysis. From 19 studies with data separated by cirrhosis status, the 5-year cumulative incidence of HCC was 0.5-6.9% in patients without cirrhosis, 4.5-21.6% in compensated cirrhosis, and 36.3-46.5% in decompensated cirrhosis. All four studies that addressed temporal changes in HCC risks consistently found the incidence rate decreased over time in patients with cirrhosis, although the findings were inconsistent in patients without cirrhosis. Six predictive scores were developed and validated to predict incident HCC during ETV/TDF therapy in CHB patients. Common scoring variables included age, sex, cirrhosis (fibrosis grade), and hepatic function. Conflicting results were reported in seven individual studies and two meta-analyses that compared ETV versus TDF. Conclusions: The residual risk of HCC remains during ETV/TDF treatment in CHB patients with cirrhosis but declines over time. Risk stratification is attainable by validated pre-Merck.

show abstract

Section: Discussionmentioning

confidence: 99%

Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review

Tseng

Hsu

et al. 2020

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…HBV and HCV are the leading causes of chronic liver disease worldwide and represent a significant public health problem. Compared with the overall global prevalence, chronic hepatitis is more common in Asian populations, including a high prevalence of HBV and HCV among Koreans [Kang et al, 2011; Wong and Goh, 2006]. However, up to 25% of cases with liver disease are not associated with HBV or HCV infection [Saravanan et al, 2009; CDC, 2010].…”

Section: Discussionmentioning

confidence: 99%

“…In Korea, HCC is the third most common type of cancer [Park, 2005] and over half of Korean patients with HCC are positive for hepatitis B surface antigen (HBsAg), while up to 20% are HCV antibody‐positive [Kim et al, 2008]. Overall the Korean population is estimated to be infected up to 5.1% by HBV and/or HCV, [Shin, 2006; Wong and Goh, 2006; Ministry of Health and Welfare, 2009]. HBV and HCV both can cause viremia [Umemura et al, 2003; Tassopoulos et al, 2008] and Vesivirus can also cause viremia [Smith et al, 2006].…”

Section: Introductionmentioning

confidence: 99%

Elevated post‐transfusion serum transaminase values associated with a highly significant trend for increasing prevalence of anti‐Vesivirus antibody in Korean patients

Lee¹,

Cho²,

Park³

et al. 2012

Journal of Medical Virology

View full text Add to dashboard Cite

A highly significant increase in anti-Vesivirus (family Caliciviridae) antibody prevalence, along the axis from healthy blood donors; donors with elevated transaminase; patients with clinical hepatitis; and patients with post-transfusion/dialysis hepatitis, has been reported in human sera from the USA and Europe. Asian samples have now been tested retrospectively using serology and enzyme immunoassay (EIA) with a Vesivirus partial-capsid antigen expressed as a fusion protein. Anti-vesiviral antibodies were measured by optical densities (OD(650)) and compared in patients separated by age, gender and Groups A-F as follows: Control Group A, an Experimental Group B, which was divided further into Group C, patients with elevated enzymes (alanine transaminase (ALT), aspartate transaminase (AST), and γ-glutamyl transpeptidase (γ-GT); Group D, patients receiving transfused blood; Group E, patients with high enzyme levels after transfusion; and Group F, hepatitis B and C positive patients. Using multivariate logistic regression analyses, a significantly greater proportion of patients receiving transfusion(s), were positive for anti-Vesivirus antibody compared with non-transfused patients (P = 0.008; OR: 3.86, 95% CI: 1.43-10.43). Also, anti-Vesivirus antibody was significantly associated with elevated biochemical liver function tests: ALT ≥ 20 IU or AST ≥ 120 IU (P = 0.017; OR: 4.23, 95% CI: 1.30-13.80). In the blood transfusion group, anti-Vesivirus antibody was significantly correlated with high enzyme levels (ALT, P = 0.018; AST, P = 0.010; γ-GT, P = 0.020). These data provide serologic evidence of vesiviral transfusion-transmission-associated disease, which could include infection of any organ system where cytopathology resulted in high levels of either ALT or AST.

show abstract

“…[51][52][53] For the remaining pathways listed in Table 6, the relationships between them and cancer development are also supported by evidence from multiple research projects. [54][55][56][57][58][59][60][61][62][63][64] In PFSNet result, large number of genes is selected as candidates for disease markers in the Colorecltal1 dataset. Further steps of disease marker identi¯cation can be performed to¯lter the candidates by using this list of genes as prior knowledge for PinnacleZ.…”

Section: Performance Comparisonmentioning

confidence: 99%

Gene-set activity toolbox (GAT): A platform for microarray-based cancer diagnosis using an integrative gene-set analysis approach

Engchuan

Meechai

Tongsima

et al. 2016

J. Bioinform. Comput. Biol.

View full text Add to dashboard Cite

Cancer is a complex disease that cannot be diagnosed reliably using only single gene expression analysis. Using gene-set analysis on high throughput gene expression profiling controlled by various environmental factors is a commonly adopted technique used by the cancer research community. This work develops a comprehensive gene expression analysis tool (gene-set activity toolbox: (GAT)) that is implemented with data retriever, traditional data pre-processing, several gene-set analysis methods, network visualization and data mining tools. The gene-set analysis methods are used to identify subsets of phenotype-relevant genes that will be used to build a classification model. To evaluate GAT performance, we performed a cross-dataset validation study on three common cancers namely colorectal, breast and lung cancers. The results show that GAT can be used to build a reasonable disease diagnostic model and the predicted markers have biological relevance. GAT can be accessed from http://gat.sit.kmutt.ac.th where GAT’s java library for gene-set analysis, simple classification and a database with three cancer benchmark datasets can be downloaded.

show abstract

Chronic Hepatitis B infection and liver cancer

Cited by 3 publications

References 14 publications

Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review

Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review

Elevated post‐transfusion serum transaminase values associated with a highly significant trend for increasing prevalence of anti‐Vesivirus antibody in Korean patients

Gene-set activity toolbox (GAT): A platform for microarray-based cancer diagnosis using an integrative gene-set analysis approach

Contact Info

Product

Resources

About